[Myeloid proliferations related to Down syndrome].
Hasegawa D.
Rinsho Ketsueki. 2019;60(9):1299-1307. doi: 10.11406/rinketsu.60.1299.
Landscape of driver mutations and their clinical effects on Down syndrome-related myeloid neoplasms.
Sato T, Yoshida K, Toki T, Kanezaki R, Terui K, Saiki R, Ojima M, Ochi Y, Mizuno S, Yoshihara M, Uechi T, Kenmochi N, Tanaka S, Matsubayashi J, Kisai K, Kudo K, Yuzawa K, Takahashi Y, Tanaka T, Yamamoto Y, Kobayashi A, Kamio T, Sasaki S, Shiraishi Y, Chiba K, Tanaka H, Muramatsu H, Hama A, Hasegawa D, Sato A, Koh K, Karakawa S, Kobayashi M, Hara J, Taneyama Y, Imai C, Hasegawa D, Fujita N, Yoshitomi M, Iwamoto S, Yamato G, Saida S, Kiyokawa N, Deguchi T, Ito M, Matsuo H, Adachi S, Hayashi Y, Taga T, Saito AM, Horibe K, Watanabe K, Tomizawa D, Miyano S, Takahashi S, Ogawa S, Ito E.
Blood. 2024 Jun 20;143(25):2627-2643. doi: 10.1182/blood.2023022247.
Management of Down Syndrome-Associated Leukemias: A Review.
Verma A, Lupo PJ, Shah NN, Hitzler J, Rabin KR.
JAMA Oncol. 2023 Sep 1;9(9):1283-1290. doi: 10.1001/jamaoncol.2023.2163.
Leukemia.
Chennamadhavuni A, Iyengar V, Mukkamalla SKR, Shimanovsky A.
2023 Jan 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–.
Inherited Predispositions to Myeloid Neoplasms: Pathogenesis and Clinical Implications.
Liu YC, Eldomery MK, Maciaszek JL, Klco JM.
Annu Rev Pathol. 2025 Jan;20(1):87-114. doi: 10.1146/annurev-pathmechdis-111523-023420. Epub 2025 Jan 2.
GATA1-related leukaemias.
Shimizu R, Engel JD, Yamamoto M.
Nat Rev Cancer. 2008 Apr;8(4):279-87. doi: 10.1038/nrc2348.
Down syndrome-related transient abnormal myelopoiesis is attributed to a specific erythro-megakaryocytic subpopulation with GATA1 mutation.
Nishinaka-Arai Y, Niwa A, Matsuo S, Kazuki Y, Yakura Y, Hiroma T, Toki T, Sakuma T, Yamamoto T, Ito E, Oshimura M, Nakahata T, Saito MK.
Haematologica. 2021 Feb 1;106(2):635-640. doi: 10.3324/haematol.2019.242693.
Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study.
Flasinski M, Scheibke K, Zimmermann M, Creutzig U, Reinhardt K, Verwer F, de Haas V, van der Velden VHJ, von Neuhoff C, Zwaan CM, Reinhardt D, Klusmann JH.
Blood Adv. 2018 Jul 10;2(13):1532-1540. doi: 10.1182/bloodadvances.2018018945.
Common Blood Test Indices for Predicting Transient Abnormal Myelopoiesis-Related Mortality in Infants with Down Syndrome.
Hawaka H, Shimokaze T, Yokosuka T, Toyoshima K, Saito T, Goto H.
Tohoku J Exp Med. 2023 Sep 20;261(1):51-56. doi: 10.1620/tjem.2023.J051. Epub 2023 Jun 22.
Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
Bista R, Lee DW, Pepper OB, Azorsa DO, Arceci RJ, Aleem E.
J Exp Clin Cancer Res. 2017 Feb 1;36(1):22. doi: 10.1186/s13046-017-0493-5.
